Ablation Still Best Option When Patient Has AF and Obesity
The PRAGUE-25 trial, led by Pavel Osmancik, MD, PhD, with the Cardiocenter at Charles University in Prague, found catheter ablation was roughly twice as effective in an intention-to-treat analysis at controlling AF at the 1-year mark compared with a combination of antiarrhythmic drugs and lifestyle modification (73% vs 34.6%).
A 'referral to [catheter ablation] in this population should not be delayed until the patient loses weight,' according to the researchers, who published their findings online on June 30 in the Journal of the American College of Cardiology simultaneously with a presentation at theNew York Valves 2025 Conference.
Obesity: A Strong Predictor of AF
AF, the most common sustained heart arrhythmia, affects about 60 million people worldwide. Obesity is one of its strongest predictors. An increase in BMI of 5 has been linked with a 19%-29% higher incidence of the rhythm disorder.
The PRAGUE trial was a randomized, noninferiority trial conducted in five centers in the Czech Republic. Patients that were included had symptomatic AF (paroxysmal, persistent, or long-standing persistent) and a BMI of 30 to 40.
Patients were randomly assigned 1:1 either to receive catheter ablation (n = 100) or a combination of medication and lifestyle changes (n = 103) from May 2021 to November 2023. Baseline characteristics were balanced, according to the researchers.
After randomization, all patients had a baseline cardiopulmonary exercise test, echocardiography, quality of life analysis, blood biochemistry testing, and a baseline 7-day electrocardiographic Holter recording.
Patients in the catheter ablation group underwent ablation within 6 weeks of randomization. Lifestyle modification was started within 4 weeks after randomization and was managed by teams of dietary specialists and physiotherapists, rather than cardiologists.
Patients in the combination therapy group lost significantly more weight at 12 months (about 6 kg, P < .001 compared to 0.35 kg in the other group), and that weight loss was maintained through the 24-month follow-up. The weight loss goal in this trial was 10%, an ambitious target in the period, especially given the physical limitations associated with AF.
Ramesh Hariharan, MD, cardiac electrophysiologist at UTHealth Houston and Memorial Hermann Health, Houston, who was not part of the study, said much of this research was conducted before the widespread use of GLP-1 receptor agonists, and those medications may help current patients achieve greater weight loss faster.
But even with greater weight loss, Hariharan said, the new findings reinforce the idea that no option alone is enough. Lifestyle changes and medicines need to accompany ablation, not replace it, he said, 'otherwise we're going to end up doing [ablations] more frequently.'
What's more, technology has improved in the last year with nonthermal pulsed field ablation, which offers 'far fewer collateral damage complications' and results in a 45-minute procedure 'compared to a 2- to 4-hour procedure before. It has made ablation a lot easier.'
Gregory M. Marcus, MD, MAS, associate chief of cardiology for research at
UCSF Health, San Francisco, said the evidence 'is already definitive that catheter ablation is superior to antiarrhythmic drugs, and there is evidence that successful lifestyle change can reduce the burden of atrial fibrillation.' But this trial is the first to show a head-to-head comparison of ablation with a combination of antiarrhythmic drugs and lifestyle changes.
Marcus said he is not convinced the findings exclude the possibility some in this patient population may still be able to treat their AF without ablation.
'For an obese, very sedentary person who drinks too much alcohol, those are, at least theoretically, the prime candidates for lifestyle modification as a way to effectively treat their Afib,' he said.
One important lesson, Marcus said, is that this adds to the growing evidence that when considering the population at large with AF, 'on average, catheter ablation is pretty definitively the most effective way to reduce the chance of atrial fibrillation recurrence.'
But some of the most interesting results were in the group who underwent lifestyle modification, he said. In addition to weight loss and improved exercise capacity, they experienced a statistically significant decrease in hemoglobin A1c concentrations of 1.4 mmol/L compared with an increase of 2.5 mmol/L in patients who received catheter ablation. 'Those are things that will prolong life and will also improve quality of life,' he said.
'Whether we're going to do an ablation or not,' Marcus added, 'we should always counsel our atrial fibrillation patients about healthy lifestyle management. There are other things to life besides atrial fibrillation.'
The study authors and Hariharan reported no relevant financial disclosures. Marcus is a consultant and was a co-founder of the startup InCarda Therapeutics, which is investigating a novel therapy for the treatment of acute AF.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
France supports Belgium's push to block US destruction of contraceptives
France has confirmed it is monitoring a US plan to incinerate millions of dollars worth of unused contraceptives in Europe – a move aid groups say is ideologically driven and medically wasteful. The contraceptives – including intrauterine devices (IUDs), implants and pills – were bought under public health programmes run by the US Agency for International Development (USAID). Since January, the supplies have been sitting in a warehouse in Geel, Belgium, after the Trump administration froze and then cancelled funding for reproductive health projects. The products, which were meant for use in low- and middle-income countries, were being stored as part of USAID's supply chain, managed by its logistics contractor Chemonics. Several media outlets have reported that the material may soon be transferred and incinerated in France, though no final decision has been confirmed. A diplomatic source told RFI that France 'firmly supports the Belgian authorities' desire to find a solution to avoid the destruction of the contraceptives' and is 'following the situation closely'. The source added that France had 'no information about any transfers that have taken place'. A US State Department spokesperson told the French news agency AFP that a preliminary decision had been made to destroy certain "abortifacient contraceptives" from USAID contracts, adding that no HIV medication or condoms would be affected. The destruction is expected to cost $167,000. The stock is valued at $9.7 million. French left urges Macron not to be complicit in US plan to bin contraceptives Redistribution offers rejected Several global organisations say they offered to collect and redistribute the supplies free of charge, but were turned down by US authorities. The International Planned Parenthood Federation (IPPF) said it proposed to recover the products in Brussels, transport them to its Dutch warehouse for repackaging, and then send them to countries in need. MSI Reproductive Choices, a UK-based group, told RFI it had offered to cover all the costs involved, including rebranding. 'We would have removed the stars from the USAID logo. It would have cost the US taxpayer nothing, nor the government,' said Sarah Shaw, MSI's advocacy director. 'We were told the US government would only sell the supplies at their purchase price. This is a situation we have never seen before.' Shaw estimated the stock would have covered Senegal's contraception needs for three years. The UN's sexual and reproductive health agency, UNFPA, also offered to buy the contraceptives but was turned down. 'This suggests the problem is not legal, but ideological,' Shaw said. 'It is a clear refusal to allow these contraceptives to be given to women in need. This US administration simply does not recognise their right to contraception.' The US State Department has described the items as 'abortifacient' – a term commonly used by anti-abortion activists to describe IUDs and other hormonal contraceptives. Since January, the Trump administration has banned any US funding to NGOs that support or promote access to abortion, even indirectly. What's stopping more men in France from getting vasectomies? French firm denies involvement Media reports have identified Veolia, a French waste management firm, as a possible contractor for the incineration. But the company told RFI it only has a framework agreement with Chemonics to handle expired products. 'The stock mentioned in Belgium is not part of this agreement,' Veolia's press office said. 'We are not responsible for its management.' Activist Danièle Gaudry, from the coalition Abortion in Europe – Women Decide, told RFI the timing of any transfer from Belgium to France remains unknown. 'We still don't know the date it will happen, and we're still trying to identify the company,' she said. France's parliament approves free contraception to be extended to women up to the age of 25 Lawmakers urge action On Saturday, French Greens leader Marine Tondelier and a group of female MPs urged President Emmanuel Macron to intervene, calling the plan 'an affront to the fundamental principles of solidarity, public health and sexual and reproductive rights that France is committed to defending'. They asked him not to become 'complicit, even indirectly, in retrograde policies' and to support NGOs ready to redistribute the contraceptives. Sarah Durocher, president of the French Family Planning association, said France had a responsibility to act. 'A government that proudly enshrines the right to abortion in its constitution must also defend access to contraception beyond its borders,' she said, in a statement issued by IPPF. The Elysée has yet to comment on the case.
Yahoo
2 hours ago
- Yahoo
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range Paris, July 31, 2025 Q2 sales growth of 10.1% at CER1 and business EPS2 of €1.59 Pharma launches increased sales by 39.8%, reaching €0.9 billion, driven by ALTUVIIIO Dupixent sales increased by 21.1% to €3.8 billion, supported by the COPD launch Vaccines sales increased by 10.3% to €1.2 billion Research and Development expenses were €1.9 billion, up 17.7% Selling, general and administrative expenses were €2.3 billion, up 7.8% Business EPS was €1.59, up 8.3% at CER and up 1.9% reported; IFRS EPS was €3.24 Pipeline progress Three regulatory approvals: Dupixent BP (US), Sarclisa NDMM, TE (EU), and MenQuadfi meningitis (US) Three phase 3 readouts, incl. itepekimab COPD (one met primary endpoint/one did not); positive SP0087 in rabies prevention Seven regulatory designations, including orphan and fast track, in rare diseases, neurology, and oncology Capital allocation Sanofi and CD&R closed the Opella transaction, creating an independent global consumer healthcare leader Acquisitions completed: Blueprint, in rare diseases/immunology, and Dren Bio's DR-0201, early-stage pipeline in immunology Acquisitions announced: Vigil, in Alzheimer's disease, and Vicebio, in respiratory vaccines, adding to the early-stage pipeline3 Sustainability Sanofi ranked the world's tenth most sustainable company and number one in Pharmaceuticals & Biotechnology by TIME Guidance In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a low double-digit percentage at CER (before share buyback), now including all expenses from newly acquired businesses4 Sanofi intends to complete its €5 billion share buyback program in 2025. 80.3% has been repurchased to date Paul Hudson, Chief Executive Officer: 'We delivered strong performance in Q2 with 10.1% sales growth. Our nine newly launched medicines and vaccines grew by 47.3%. Eight years after market introduction, Dupixent grew by more than 20%, supported by the COPD launch. Based on strong sales performance in H1, we are refining our 2025 sales guidance to the upper end of our previous range. At the same time, we confirm our guidance of a strong business EPS rebound, which now includes all expenses from newly acquired businesses. Our pipeline continues to make progress despite the mixed results with itepekimab in COPD. We are progressing the data analysis and once finished, we will discuss with regulatory authorities. We remain steadfast in our dedication to bringing new medicines and vaccines to patients. We eagerly anticipate several important phase 3 data readouts in the second half of the year, including amlitelimab in atopic dermatitis and tolebrutinib in primary progressive multiple sclerosis. Earlier in July, we successfully closed the acquisition of Blueprint in rare diseases, and we are anticipating the closing of the Vigil acquisition in neurology during Q3. Sanofi will remain focused on strategically redeploying capital towards growth and differentiated science with attractive financial returns. We continue to advance our strategy as an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth.' Q2 2025 Change Change at CER H1 2025 Change Change at CER IFRS net sales reported €9,994m +6.0% +10.1% €19,889m +8.3% +9.9% IFRS net income reported €3,939m +253.9% — €5,812m +158.8% — IFRS EPS reported €3.24 +264.0% — €4.74 +163.3% — Free cash flow5 €1,429m +65.8% — €2,458m +474.3% — Business operating income €2,461m -2.4% +3.3 % €5,363m +8.6% +10.8% Business net income €1,940m -0.6% +5.1 % €4,152m +7.6% +9.8% Business EPS €1.59 +1.9% +8.3% €3.39 +9.7% +12.0% 1 Changes in net sales are at constant exchange rates (CER) unless stated otherwise (definition in Appendix 9). 2 To facilitate an understanding of operational performance, Sanofi comments on the business net income, a non-IFRS financial measure (definition in Appendix 9). The income statement is in Appendix 3 and a reconciliation of net income as reported under IFRS to business net income is in Appendix 4. 3 Subject to closing conditions detailed overleaf. 4 Applying July 2025 average currency exchange rates, the currency impacts are estimated at around -4% on sales and at around -6% on business EPS. 5 Free cash flow is a non-IFRS financial measure (definition in Appendix 9). Attachment Press releaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
This mobility test takes just seconds — and it could predict how well you'll age
When you buy through links on our articles, Future and its syndication partners may earn a commission. A recent study published in the European Journal of Preventive Cardiology has brought a surprisingly simple test into the spotlight. It is called the sitting-rising test. Can you sit down on the floor and then stand back up again, without using your hands, arms, knees or the nearest bit of furniture for support? Researchers found that people who could do this with little to no assistance were more likely to live longer than those who struggled. The test gives you a score out of 10, taking away points each time you use a hand or knee to steady yourself. Scoring low was associated with a greater risk of earlier mortality during the study period. But before you start stretching on the living room rug, let's break down what this test is really measuring and how it could help you take stock of your overall health. Why this matters to you The sitting-rising test measures more than just mobility. It also challenges your strength, balance, and coordination, which are important movement skills you use every day without perhaps realizing. Whether you have stood up while holding a toddler or gotten up after working on flat-pack furniture, your whole body needs to work smoothly together. As we get older, moving with confidence and control becomes more and more important. Good balance and strength help reduce the risk of falls, make it easier to stay active, and help you maintain your independence. So, how easily you can get off the floor now could give you a glimpse of how capable and mobile you are likely to be in the years ahead. How to try the test Clear a bit of floor space and begin by standing. You will then cross one leg behind the other and lower yourself down to a seated position on the floor. Then return to standing the same way. Try not to use your hands, knees or arms for support. Each time you do, subtract one point from your score out of 10. Scoring seven or above is considered good. While anything lower might suggest an area worth improving. But don't panic if you don't pass with flying colors. This test is based on just one study, and while the results are interesting, it is not the be all and end all of your health. This is simply a quick way to spot potential areas to work on so you can move more comfortably and feel stronger as you age. How to improve your score If your hips feel stiff, your balance is a little off, or your legs don't feel as strong as they used to, that can be a helpful place to begin. You are not alone in feeling that way, and the good news is that there are gentle ways to rebuild strength and confidence in how you move. Functional strength workouts that focus on the legs and core can gradually help you feel more stable and supported. Likewise, adding short mobility sessions may ease stiffness and make everyday movement feel more comfortable. You might also find that something like yoga works well, as it combines balance, flexibility and strength in a way that can be adapted to your needs. We have tested some of the best yoga mats to help make getting started a little easier. They are, of course, great for yoga practice, but also provide a comfortable and supportive base for all kinds of workouts and floor exercises. More from Tom's Guide Do ginger shots actually work? I took one every day for a week to find out How running for 75 minutes a week could help you live longer — and feel younger Forget hour-long workouts — new study says this 5-minute routine improves your strength and mental health
